Andrew Tjong Hauw Kwa, MD
Internal Medicine · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 23
- 5 carriers
- Offices
- 2
Offices
2 locations · Apex Cardiology of Silicon Valley A Medical Partnership · Physician Services at El Camino Hospital
Hospitals listed: El Camino Health · Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
23 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kwa’s office at (408) 369-7500 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
23 of 23 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
California Medical Board record
Licence A93963 · Current
Licensed to practise in California · since 2006 · expires 2027-06-30 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
20 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 79.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Appropriate Treatment for Upper Respiratory Infection (URI)As Medicare defines this measure | 100% | 24 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 96%That's most of the people this applied to. | 28 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 66%That's more than half. | 722 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 0%That's few of the people this applied to. Better on this measure. | 79 |
| Breast cancer screeningEligible women who got a mammogram | 27%That's less than half. | 254 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 50%That's more than half. | 224 |
| Checked for fall riskOlder patients screened for fall risk | 99%That's most of the people this applied to. | 984 |
| Colon cancer screeningEligible adults who got a colon cancer test | 25%That's less than half. | 814 |
See the other 12 measures
| Daily function assessedPatients whose ability to manage daily activities was assessed | 0%That's few of the people this applied to. | 52 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 99%That's most of the people this applied to. | 1,425 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 2%That's few of the people this applied to. | 119 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 50%That's more than half. Worse on this measure. | 119 |
| HIV screeningEligible patients who were screened for HIV | 17%That's few of the people this applied to. | 589 |
| Medications listed in the chartVisits where the current medication list was documented | 97%That's most of the people this applied to. | 3,300 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 587 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 99%That's most of the people this applied to. | 957 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 3%That's few of the people this applied to. Better on this measure. | 1,023 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 30% | 1,768 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 80%That's most of the people this applied to. | 1,137 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 66%That's more than half. | 1,485 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- Improved the patient portal
- Offers telehealth visits
- ONC-ACB Surveillance Attestation
- Reports cases to public health electronically
- Reports immunizations to the state registry
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$650,155
Medicare paid this office $650,155 for 1,062 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 570 | $104,140 | $115 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 96 | $90,654 | $925 |
| Long return visit (40+ min) | 231 | $76,421 | $165 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 316 | $63,743 | $196 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 111 | $44,909 | $405 |
See all 37 services
| Return visit (30+ min) | 570 | $104,140 | $115 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 96 | $90,654 | $925 |
| Long return visit (40+ min) | 231 | $76,421 | $165 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 316 | $63,743 | $196 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 111 | $44,909 | $405 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 45 | $23,034 | $63 |
| New patient visit (45+ min) | 133 | $18,622 | $140 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 111 | $17,405 | $78 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 15 | $17,291 | $110 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 589 | $16,817 | $14 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 67 | $16,205 | $242 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $13,696 | $108 |
| Critical care, first 30-74 minutes | 22 | $9,104 | $190 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 16 | $8,864 | $492 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $8,069 | $155 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 120 | $7,989 | $65 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 41 | $7,987 | $195 |
| New patient visit (60+ min) | 37 | $6,932 | $187 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 91 | $5,479 | $60 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 72 | $5,204 | $24 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 64 | $4,796 | $26 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 187 | $2,753 | $14 |
| Ultrasound of both sides of head and neck blood flow | 18 | $2,702 | $142 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 95 | $2,247 | $23 |
| Programming of dual lead pacemaker system | 17 | $1,578 | $79 |
| Injection, regadenoson, 0.1 mg | 75 | $1,517 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 177 | $1,381 | $7 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 13 | $1,265 | $33 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 15 | $1,207 | $80 |
| External shock to heart to regulate heart beat | 11 | $1,196 | $100 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 80 | $996 | $6 |
| Anticoagulant management of patient taking warfarin | 17 | $923 | $10 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 13 | $796 | $61 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 58 | $643 | $11 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 21 | $473 | $22 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 18 | $229 | $13 |
| Ultrasonic guidance for blood vessel access | 12 | $146 | $12 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 22 | More than 52% of doctors who do this |
| Leg revascularization (restoring blood flow) | 1-10 | None |
Who their Medicare patients are
1,062 Original Medicare patients in 2024. Average age 78 · Under 65 2% · 85 and older 25% · Women 50% · Also on Medicaid 7% · Health risk score 1.38. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Coronary heart disease 41% · Atrial fibrillation 36% · Diabetes 33% · Chronic kidney disease 26% · Heart failure 25% · Cancer 20% · Stroke 16% · COPD 15% · Depression 15% · Dementia 11%.
The office billed $1,558,716, Medicare allowed $847,037 and paid $650,155; for 9,629 services of 88 kinds; $31,333 of it was for drugs given in the office and $618,822 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,062 | 9,629 | 78 | 1.38 | $1,558,716 | $650,155 |
| 2023 | 1,091 | 5,812 | 79 | 1.48 | $1,536,659 | $632,299 |
| 2022 | 1,084 | 6,633 | 78 | 1.36 | $1,705,702 | $697,833 |
| 2021 | 1,094 | 6,777 | 78 | 1.43 | $1,791,994 | $730,983 |
| 2020 | 940 | 5,527 | 78 | 1.48 | $1,481,786 | $600,422 |
| 2019 | 1,067 | 5,798 | 78 | 1.44 | $1,583,104 | $615,338 |
| 2018 | 1,045 | 5,446 | 78 | 1.43 | $1,382,378 | $500,822 |
| 2017 | 1,079 | 5,442 | 78 | 1.52 | $1,398,346 | $528,511 |
| 2016 | 984 | 4,751 | 78 | 1.55 | $1,363,171 | $495,997 |
| 2015 | 815 | 4,184 | 78 | 1.48 | $1,105,235 | $423,356 |
| 2014 | 681 | 7,718 | 77 | 1.37 | $1,191,060 | $453,288 |
| 2013 | 606 | 3,251 | 77 | 1.45 | $1,060,720 | $374,385 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 33 services
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 100 | $103,303 | $948 |
| Return visit (30+ min) | 527 | $95,150 | $112 |
| Long return visit (40+ min) | 247 | $76,967 | $163 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 311 | $64,368 | $200 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 112 | $45,908 | $410 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 92 | $22,903 | $110 |
| Critical care, first 30-74 minutes | 29 | $17,578 | $191 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 112 | $17,491 | $78 |
| New patient visit (45+ min) | 111 | $14,961 | $135 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 57 | $14,424 | $32 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $12,012 | $156 |
| Injection, regadenoson, 0.1 mg | 66 | $10,845 | None |
| New patient visit (60+ min) | 44 | $8,657 | $197 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 36 | $8,384 | $233 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 118 | $7,446 | $63 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 108 | $6,898 | $62 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 42 | $6,708 | $23 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 34 | $6,436 | $189 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 78 | $5,176 | $24 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 67 | $4,762 | $26 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 59 | $4,021 | $68 |
| Ultrasound of both sides of head and neck blood flow | 26 | $4,018 | $155 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 19 | $3,772 | $23 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 100 | $2,556 | $23 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 158 | $2,289 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 239 | $1,952 | $7 |
| Programming of dual lead pacemaker system | 19 | $1,724 | $78 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 107 | $1,616 | $6 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 13 | $1,191 | $32 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $567 | $22 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 49 | $550 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 23 | $297 | $13 |
| Ultrasonic guidance for blood vessel access | 13 | $162 | $12 |
2022: 38 services
| Return visit (30+ min) | 569 | $112,160 | $111 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 99 | $103,511 | $995 |
| Long return visit (40+ min) | 231 | $78,946 | $165 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 310 | $65,016 | $198 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 153 | $64,432 | $418 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 107 | $25,069 | $92 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 153 | $24,766 | $80 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 90 | $17,306 | $178 |
| Injection, regadenoson, 0.1 mg | 88 | $17,091 | None |
| New patient visit (45+ min) | 109 | $15,884 | $146 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 95 | $15,219 | $25 |
| Critical care, first 30-74 minutes | 27 | $14,656 | $193 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 56 | $12,091 | $208 |
| New patient visit (60+ min) | 60 | $12,071 | $201 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 156 | $9,833 | $62 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 61 | $9,474 | $23 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 17 | $7,771 | $457 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 100 | $7,465 | $72 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 99 | $6,731 | $64 |
| Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel | 11 | $6,198 | $563 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 20 | $4,819 | $241 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 67 | $4,813 | $26 |
| Ultrasound of both sides of head and neck blood flow | 29 | $4,458 | $154 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 18 | $4,043 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 72 | $3,828 | $25 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $3,046 | $98 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 99 | $2,456 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 151 | $2,192 | $13 |
| Programming of dual lead pacemaker system | 20 | $1,954 | $85 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 124 | $1,942 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 194 | $1,599 | $7 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 19 | $1,596 | $33 |
| External shock to heart to regulate heart beat | 11 | $1,205 | $100 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 74 | $847 | $11 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 12 | $750 | $63 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $507 | $24 |
| Ultrasonic guidance for blood vessel access | 18 | $233 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 11 | $146 | $13 |
2021: 39 services
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 124 | $103,174 | $788 |
| Return visit (30+ min) | 526 | $97,005 | $114 |
| Long return visit (40+ min) | 223 | $78,682 | $160 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 147 | $65,734 | $447 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 305 | $64,824 | $204 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 129 | $28,190 | $95 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 130 | $24,892 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 111 | $22,163 | $182 |
| Critical care, first 30-74 minutes | 39 | $21,895 | $199 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 86 | $16,944 | $26 |
| New patient visit (45+ min) | 112 | $16,426 | $147 |
| Injection, regadenoson, 0.1 mg | 78 | $14,848 | None |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 60 | $11,816 | $25 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 155 | $9,867 | $64 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 45 | $9,483 | $211 |
| New patient visit (60+ min) | 41 | $8,588 | $209 |
| Telephone medical discussion with physician, 21-30 minutes | 60 | $7,996 | $121 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 115 | $7,602 | $64 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 95 | $7,517 | $75 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 15 | $7,214 | $481 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 26 | $6,631 | $255 |
| Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel | 11 | $6,367 | $579 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 67 | $5,198 | $26 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 75 | $4,973 | $27 |
| Ultrasound of both sides of head and neck blood flow | 26 | $4,233 | $163 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 18 | $3,807 | $24 |
| Ultrasound of leg arteries or artery grafts | 19 | $3,651 | $183 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 124 | $3,116 | $24 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 16 | $2,650 | $156 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 148 | $2,448 | $6 |
| Programming of dual lead pacemaker system | 24 | $2,042 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 215 | $1,677 | $7 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 83 | $1,380 | $14 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 13 | $1,300 | $35 |
| External shock to heart to regulate heart beat | 11 | $1,235 | $103 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 16 | $1,030 | $64 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 83 | $986 | $11 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $928 | $66 |
| Ultrasonic guidance for blood vessel access | 34 | $454 | $13 |
2020: 40 services
| Long return visit (40+ min) | 255 | $86,211 | $134 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 166 | $72,556 | $434 |
| Return visit (30+ min) | 463 | $71,999 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 282 | $61,159 | $210 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 70 | $57,568 | $789 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 166 | $32,476 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 96 | $20,598 | $97 |
| Critical care, first 30-74 minutes | 28 | $18,923 | $201 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 90 | $17,440 | $188 |
| Injection, regadenoson, 0.1 mg | 87 | $16,397 | None |
| New patient visit (45+ min) | 88 | $12,061 | $137 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 175 | $11,449 | $64 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 45 | $10,346 | $225 |
| New patient visit (60+ min) | 53 | $9,614 | $181 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 67 | $5,814 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 79 | $5,653 | $69 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 30 | $5,174 | $25 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 21 | $5,134 | $244 |
| Ultrasound of both sides of head and neck blood flow | 32 | $4,596 | $144 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 61 | $3,522 | $28 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,420 | $67 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 55 | $3,324 | $29 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 15 | $2,994 | $25 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 17 | $2,961 | $25 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 138 | $2,426 | $6 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 12 | $2,364 | $197 |
| Ultrasound of leg arteries or artery grafts | 15 | $2,227 | $148 |
| Programming of dual lead pacemaker system | 28 | $2,017 | $56 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 68 | $1,778 | $25 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 105 | $1,761 | $16 |
| External shock to heart to regulate heart beat | 11 | $1,351 | $104 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,332 | $102 |
| Short return visit (20+ min) | 17 | $1,329 | $74 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 139 | $1,283 | $7 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 18 | $869 | $46 |
| External ekg recording for more than 48 hours up to 21 days | 31 | $841 | $25 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 66 | $803 | $11 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 31 | $718 | $22 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $504 | $23 |
| Ultrasonic guidance for blood vessel access | 12 | $212 | $13 |
2019: 40 services
| Return visit (30+ min) | 571 | $86,883 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 175 | $78,214 | $435 |
| Long return visit (40+ min) | 244 | $70,610 | $134 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 256 | $57,023 | $208 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 176 | $34,313 | $97 |
| Critical care, first 30-74 minutes | 53 | $24,414 | $198 |
| Injection, regadenoson, 0.1 mg | 112 | $20,676 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 106 | $20,552 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $19,015 | $181 |
| New patient visit (45+ min) | 99 | $14,707 | $149 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 65 | $14,034 | $206 |
| Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel | 21 | $12,190 | $580 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 186 | $11,989 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 87 | $10,141 | $66 |
| New patient visit (60+ min) | 52 | $10,051 | $193 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 18 | $9,295 | $443 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 96 | $6,934 | $68 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 21 | $4,960 | $236 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 14 | $4,485 | $299 |
| Ultrasound of leg arteries or artery grafts | 14 | $3,936 | $232 |
| Ultrasound of both sides of head and neck blood flow | 24 | $3,173 | $132 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 167 | $2,940 | $6 |
| Programming of dual lead pacemaker system | 35 | $2,740 | $60 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 13 | $2,128 | $164 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 109 | $1,991 | $16 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 16 | $1,947 | $22 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 13 | $1,801 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 37 | $1,738 | $26 |
| Short return visit (20+ min) | 25 | $1,727 | $69 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 34 | $1,687 | $26 |
| External shock to heart to regulate heart beat | 11 | $1,623 | $101 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 22 | $1,430 | $12 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 15 | $1,393 | $82 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 115 | $1,380 | $11 |
| External ekg recording for more than 48 hours up to 21 days | 44 | $1,352 | $28 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 44 | $1,182 | $25 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 149 | $1,178 | $7 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 34 | $884 | $22 |
| Programming of single lead pacemaker system | 11 | $659 | $55 |
| Ultrasonic guidance for blood vessel access | 44 | $628 | $13 |
2018: 39 services
| Return visit (30+ min) | 647 | $100,404 | $94 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 146 | $63,588 | $433 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 284 | $60,844 | $206 |
| Long return visit (40+ min) | 151 | $32,348 | $130 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 148 | $28,115 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 90 | $18,437 | $181 |
| Critical care, first 30-74 minutes | 36 | $17,050 | $196 |
| New patient visit (45+ min) | 118 | $16,673 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $16,571 | $93 |
| Injection, regadenoson, 0.1 mg | 90 | $15,661 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 95 | $12,682 | $65 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 48 | $11,371 | $237 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 155 | $9,608 | $61 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 39 | $8,014 | $205 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 111 | $7,587 | $65 |
| Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel | 11 | $6,818 | $568 |
| New patient visit (60+ min) | 38 | $6,486 | $171 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 12 | $6,325 | $452 |
| Programming of dual lead pacemaker system | 40 | $3,269 | $52 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 34 | $2,995 | $83 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 154 | $2,942 | $6 |
| Ultrasound of both sides of head and neck blood flow | 26 | $2,769 | $106 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 16 | $2,740 | $22 |
| Ultrasound of leg arteries or artery grafts | 14 | $2,617 | $187 |
| Short return visit (20+ min) | 39 | $2,513 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 139 | $2,348 | $16 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 45 | $2,158 | $27 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 25 | $1,961 | $12 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 40 | $1,959 | $26 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 15 | $1,916 | $23 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 11 | $1,672 | $152 |
| Complete ultrasound study of arm and leg arteries | 22 | $1,292 | $59 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 45 | $1,084 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 121 | $994 | $7 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 64 | $739 | $11 |
| External ekg recording for more than 48 hours up to 21 days | 25 | $681 | $26 |
| Programming of single lead pacemaker system | 14 | $668 | $42 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 25 | $588 | $23 |
| Ultrasonic guidance for blood vessel access | 29 | $372 | $13 |
2017: 38 services
| Return visit (30+ min) | 650 | $110,718 | $91 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 147 | $67,320 | $449 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 254 | $59,290 | $228 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 147 | $28,625 | $95 |
| Long return visit (40+ min) | 134 | $27,088 | $131 |
| Critical care, first 30-74 minutes | 36 | $24,413 | $195 |
| New patient visit (45+ min) | 132 | $18,178 | $138 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 88 | $18,014 | $178 |
| Injection, regadenoson, 0.1 mg | 94 | $16,662 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 94 | $15,288 | $65 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 48 | $13,017 | $271 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $12,620 | $93 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 157 | $10,649 | $65 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 41 | $9,415 | $219 |
| New patient visit (60+ min) | 34 | $6,468 | $190 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 11 | $5,826 | $485 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 87 | $5,315 | $57 |
| Ultrasound of leg arteries or artery grafts | 18 | $5,301 | $265 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 18 | $5,218 | $290 |
| Ultrasound of both sides of head and neck blood flow | 31 | $3,611 | $116 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 135 | $2,658 | $6 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 27 | $2,582 | $86 |
| Programming of dual lead pacemaker system | 37 | $2,573 | $50 |
| Complete ultrasound study of arm and leg arteries | 39 | $2,494 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 123 | $2,306 | $16 |
| Short return visit (20+ min) | 27 | $1,799 | $67 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 41 | $1,565 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 34 | $1,353 | $28 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 160 | $1,336 | $8 |
| External shock to heart to regulate heart beat | 12 | $1,309 | $94 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 16 | $1,215 | $24 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 77 | $927 | $11 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 13 | $912 | $13 |
| External ekg recording for more than 48 hours up to 21 days | 31 | $881 | $28 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 36 | $848 | $17 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 31 | $776 | $24 |
| Ultrasonic guidance for blood vessel access | 41 | $602 | $13 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 14 | $544 | $34 |
2016: 37 services
| Return visit (30+ min) | 571 | $109,961 | $90 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 147 | $71,578 | $484 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 227 | $52,254 | $221 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 147 | $27,728 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 141 | $21,171 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 104 | $20,811 | $176 |
| Critical care, first 30-74 minutes | 34 | $20,711 | $192 |
| Long return visit (40+ min) | 137 | $17,519 | $112 |
| Injection, regadenoson, 0.1 mg | 86 | $14,408 | None |
| New patient visit (45+ min) | 90 | $12,623 | $140 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 44 | $11,690 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $10,860 | $91 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 155 | $9,631 | $62 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 33 | $8,737 | $265 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 115 | $6,794 | $56 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 12 | $6,334 | $422 |
| New patient visit (60+ min) | 33 | $5,405 | $164 |
| Complete ultrasound study of arm and leg arteries | 28 | $4,198 | $140 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 13 | $3,794 | $292 |
| Ultrasound of both sides of head and neck blood flow | 18 | $3,370 | $187 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 36 | $3,086 | $81 |
| Ultrasound of leg arteries or artery grafts | 17 | $3,074 | $181 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 11 | $2,338 | $213 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 12 | $2,326 | $194 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 114 | $2,065 | $16 |
| Programming of dual lead pacemaker system | 26 | $1,504 | $47 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 77 | $1,273 | $6 |
| Programming of single lead pacemaker system | 17 | $1,064 | $39 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 25 | $957 | $28 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 106 | $832 | $7 |
| Hospital observation care on day of discharge | 12 | $774 | $65 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 24 | $651 | $24 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 16 | $517 | $29 |
| External ekg recording for more than 48 hours up to 21 days | 16 | $468 | $28 |
| Ultrasonic guidance for blood vessel access | 32 | $464 | $13 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 16 | $401 | $24 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 21 | $389 | $16 |
2015: 30 services
| Return visit (30+ min) | 474 | $92,288 | $91 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 123 | $62,690 | $502 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 181 | $41,035 | $217 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 124 | $33,295 | $132 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $18,544 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 106 | $16,984 | $65 |
| Critical care, first 30-74 minutes | 34 | $16,682 | $196 |
| New patient visit (45+ min) | 90 | $13,204 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $11,712 | $92 |
| Injection, regadenoson, 0.1 mg | 68 | $11,284 | None |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 45 | $9,796 | $208 |
| Long return visit (40+ min) | 55 | $9,277 | $127 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 129 | $8,651 | $65 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 13 | $7,115 | $474 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $6,283 | $57 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 20 | $5,360 | $268 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 16 | $5,225 | $327 |
| New patient visit (60+ min) | 26 | $4,707 | $181 |
| Ultrasound of leg arteries or artery grafts | 14 | $3,524 | $235 |
| Complete ultrasound study of arm and leg arteries | 21 | $2,956 | $141 |
| Ultrasound of both sides of head and neck blood flow | 13 | $2,586 | $199 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 27 | $2,130 | $79 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 116 | $2,055 | $16 |
| Programming of dual lead pacemaker system | 23 | $1,617 | $48 |
| Hospital observation care on day of discharge | 14 | $921 | $66 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 105 | $909 | $8 |
| External ekg recording for more than 48 hours up to 21 days | 15 | $364 | $24 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 15 | $362 | $24 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 12 | $361 | None |
| Ultrasonic guidance for blood vessel access | 24 | $336 | $13 |
2014: 32 services
| Return visit (30+ min) | 464 | $91,503 | $94 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 135 | $67,266 | $491 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 161 | $36,709 | $224 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 135 | $35,990 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 122 | $21,652 | $63 |
| Critical care, first 30-74 minutes | 31 | $19,540 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 99 | $19,226 | $176 |
| New patient visit (45+ min) | 98 | $13,750 | $140 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 24 | $12,918 | $478 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $10,998 | $92 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 147 | $9,805 | $65 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 89 | $9,484 | None |
| Long return visit (40+ min) | 62 | $8,970 | $130 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 43 | $8,364 | $195 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 25 | $6,924 | $277 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 103 | $6,258 | $57 |
| New patient visit (60+ min) | 29 | $5,300 | $183 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 17 | $5,252 | $309 |
| Complete ultrasound study of arm and leg arteries | 32 | $4,484 | $140 |
| Ultrasound of leg arteries or artery grafts | 14 | $3,296 | $235 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 13 | $2,775 | $198 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 32 | $2,598 | $79 |
| Ultrasound of both sides of head and neck blood flow | 13 | $2,423 | $186 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 135 | $2,206 | $16 |
| Injection, regadenoson, 0.1 mg | 13 | $2,160 | None |
| Programming of dual lead pacemaker system | 26 | $1,902 | $51 |
| Insertion of tube into chest or arm artery, each first order branch | 14 | $1,485 | $106 |
| Hospital observation care on day of discharge | 18 | $1,239 | $65 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 15 | $1,193 | $80 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 13 | $637 | $34 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $196 | $14 |
| Ultrasonic guidance for blood vessel access | 13 | $186 | $13 |
2013: 36 services
| Return visit (30+ min) | 308 | $52,687 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 72 | $37,315 | $511 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 132 | $25,115 | $186 |
| Critical care, first 30-74 minutes | 38 | $23,192 | $190 |
| Long return visit (40+ min) | 144 | $20,742 | $130 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 72 | $19,150 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 108 | $18,841 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 100 | $18,712 | $173 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 24 | $13,875 | $434 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 62 | $12,767 | $199 |
| New patient visit (45+ min) | 81 | $11,489 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $7,526 | $90 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 128 | $7,471 | $55 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 19 | $7,408 | $274 |
| New patient visit (60+ min) | 34 | $6,321 | $186 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 81 | $5,579 | $66 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 24 | $5,578 | $232 |
| Injection, regadenoson, 0.1 mg | 27 | $4,555 | None |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 24 | $4,112 | None |
| Complete ultrasound study of arm and leg arteries | 24 | $3,585 | $149 |
| Insertion of tube into chest or arm artery, each first order branch | 29 | $3,001 | $103 |
| Ultrasound of both sides of head and neck blood flow | 15 | $2,825 | $188 |
| Ultrasound of leg arteries or artery grafts | 14 | $2,641 | $189 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 12 | $2,368 | $197 |
| Insertion of tube into chest or arm artery, initial second order branch | 19 | $2,358 | $124 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 26 | $2,143 | $82 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 108 | $1,964 | $17 |
| Hospital observation care on day of discharge | 23 | $1,724 | $64 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 97 | $1,638 | $6 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 20 | $1,538 | $77 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 18 | $1,387 | $77 |
| Short return visit (20+ min) | 14 | $956 | $68 |
| Programming of dual lead pacemaker system | 13 | $861 | $54 |
| Injection for imaging of aorta above heart valve with review by radiologist | 12 | $505 | $42 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 12 | $381 | $27 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $320 | $17 |
Medicaid work
$108 in 2024
Medicaid paid $108 for 48 billed services this clinician did in 2024, up to 24 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 48 | $108 |
| 2024 | 48 | 1 | 24 | $108 |
| 2023 | 50 | 1 | 26 | $276 |
| 2022 | 55 | 1 | 22 | $223 |
| 2021 | 42 | 1 | 14 | $239 |
| 2019 | 28 | 1 | 13 | $120 |
| 2018 | 16 | 1 | 14 | $82 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 50 | $276 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 55 | $223 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 42 | $239 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 28 | $120 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 16 | $82 |
Drugs they prescribed that Part D paid
$1,542,555
Pharmacies billed $1,542,555 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 5,778) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
4,678 generic and 1,100 brand-name prescriptions · $1,542,555 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 532 | $775,763 | $1,458 |
| Xarelto | 103 | $153,922 | $1,494 |
| Repatha Sureclick | 148 | $131,854 | $891 |
| Entresto | 77 | $102,460 | $1,331 |
| Farxiga | 46 | $56,973 | $1,239 |
See all 50 drugs
| Eliquis | 532 | $775,763 | $1,458 |
| Xarelto | 103 | $153,922 | $1,494 |
| Repatha Sureclick | 148 | $131,854 | $891 |
| Entresto | 77 | $102,460 | $1,331 |
| Farxiga | 46 | $56,973 | $1,239 |
| Multaq | 28 | $43,232 | $1,544 |
| Brilinta | 40 | $39,494 | $987 |
| Vascepa | 22 | $18,254 | $830 |
| Livalo | 14 | $13,501 | $964 |
| Metoprolol | 766 | $11,663 | $15 |
| Flecainide Acetate | 163 | $9,007 | $55 |
| Diltiazem 24hr Er (Cd) | 85 | $5,956 | $70 |
| Atorvastatin | 479 | $5,835 | $12 |
| Losartan | 443 | $5,677 | $13 |
| Rosuvastatin | 267 | $4,900 | $18 |
| Ezetimibe | 137 | $4,299 | $31 |
| Amlodipine Besylate | 493 | $3,855 | $8 |
| Ranolazine Er | 21 | $3,327 | $158 |
| Nebivolol | 46 | $3,312 | $72 |
| Bumetanide | 41 | $2,987 | $73 |
| Losartan-Hydrochlorothiazide | 108 | $2,517 | $23 |
| Furosemide | 244 | $2,151 | $9 |
| Sotalol | 41 | $1,207 | $29 |
| Lisinopril | 142 | $1,207 | $8 |
| Metoprolol | 149 | $1,177 | $8 |
| Carvedilol | 96 | $1,164 | $12 |
| Clopidogrel | 81 | $1,131 | $14 |
| Ezetimibe-Simvastatin | 16 | $1,075 | $67 |
| Potassium Chloride | 45 | $1,038 | $23 |
| Hydrochlorothiazide | 178 | $981 | $6 |
| Fenofibrate | 11 | $981 | $89 |
| Olmesartan Medoxomil | 18 | $969 | $54 |
| Hydralazine | 43 | $938 | $22 |
| Valsartan-Hydrochlorothiazide | 24 | $784 | $33 |
| Sotalol Af | 12 | $696 | $58 |
| Atenolol | 80 | $660 | $8 |
| Digoxin | 14 | $622 | $44 |
| Amiodarone | 21 | $614 | $29 |
| Isosorbide Mononitrate Er | 38 | $573 | $15 |
| Fenofibrate | 16 | $477 | $30 |
| Verapamil Er | 25 | $470 | $19 |
| Spironolactone | 41 | $356 | $9 |
| Simvastatin | 34 | $348 | $10 |
| Warfarin | 23 | $303 | $13 |
| Pantoprazole | 19 | $260 | $14 |
| Enalapril Maleate | 13 | $255 | $20 |
| Valsartan | 16 | $227 | $14 |
| Pravastatin | 23 | $179 | $8 |
| Benazepril | 12 | $127 | $11 |
| Ramipril | 15 | $125 | $8 |
Year by year
| 2024 | 5,778 | 721 | 0% (0) | 19% | $1,542,555 |
| 2023 | 5,803 | 737 | 0% (0) | 18% | $1,555,904 |
| 2022 | 5,988 | 761 | None | 18% | $1,590,058 |
| 2021 | 5,967 | 743 | None | 20% | $1,233,786 |
| 2020 | 6,024 | 699 | None | 22% | $1,186,758 |
| 2019 | 5,503 | 667 | 0% (0) | 22% | $1,015,780 |
| 2018 | 5,317 | 624 | None | 20% | $725,174 |
| 2017 | 5,708 | 597 | None | 24% | $578,048 |
| 2016 | 5,588 | 564 | None | 25% | $488,297 |
| 2015 | 3,804 | 383 | None | 23% | $265,570 |
| 2014 | 3,144 | 318 | 0% (0) | 25% | $184,256 |
| 2013 | 1,053 | 199 | 0% (0) | 25% | $61,191 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 51 drugs
| Eliquis | 552 | $792,534 | $1,436 |
| Xarelto | 96 | $149,012 | $1,552 |
| Repatha Sureclick | 141 | $110,791 | $786 |
| Entresto | 52 | $89,098 | $1,713 |
| Brilinta | 30 | $25,780 | $859 |
| Farxiga | 15 | $21,201 | $1,413 |
| Livalo | 20 | $17,658 | $883 |
| Metoprolol | 746 | $15,087 | $20 |
| Vascepa | 13 | $14,357 | $1,104 |
| Flecainide Acetate | 156 | $9,659 | $62 |
| Icosapent Ethyl | 14 | $8,973 | $641 |
| Diltiazem 24hr Er (Cd) | 103 | $7,312 | $71 |
| Ezetimibe | 123 | $6,877 | $56 |
| Losartan | 449 | $6,689 | $15 |
| Atorvastatin | 504 | $6,672 | $13 |
| Rosuvastatin | 237 | $5,963 | $25 |
| Ranolazine Er | 23 | $4,609 | $200 |
| Nebivolol | 41 | $4,554 | $111 |
| Amlodipine Besylate | 494 | $4,231 | $9 |
| Potassium Chloride | 61 | $3,582 | $59 |
| Bumetanide | 45 | $2,631 | $58 |
| Losartan-Hydrochlorothiazide | 109 | $2,363 | $22 |
| Furosemide | 245 | $2,183 | $9 |
| Ezetimibe-Simvastatin | 17 | $1,714 | $101 |
| Clopidogrel | 92 | $1,704 | $19 |
| Sotalol | 40 | $1,661 | $42 |
| Hydralazine | 45 | $1,540 | $34 |
| Metoprolol | 149 | $1,517 | $10 |
| Carvedilol | 95 | $1,468 | $15 |
| Atenolol | 88 | $1,163 | $13 |
| Olmesartan Medoxomil | 22 | $1,076 | $49 |
| Sotalol Af | 12 | $1,049 | $87 |
| Amiodarone | 22 | $1,006 | $46 |
| Isosorbide Mononitrate Er | 41 | $1,006 | $25 |
| Diltiazem 24hr Er (Xr) | 13 | $935 | $72 |
| Hydrochlorothiazide | 206 | $820 | $4 |
| Lisinopril | 128 | $730 | $6 |
| Simvastatin | 54 | $710 | $13 |
| Warfarin | 39 | $636 | $16 |
| Verapamil Er | 24 | $625 | $26 |
| Fenofibrate | 18 | $607 | $34 |
| Digoxin | 23 | $564 | $25 |
| Valsartan | 20 | $532 | $27 |
| Valsartan-Hydrochlorothiazide | 13 | $504 | $39 |
| Enalapril Maleate | 17 | $426 | $25 |
| Spironolactone | 43 | $398 | $9 |
| Benazepril | 25 | $322 | $13 |
| Pravastatin | 24 | $316 | $13 |
| Pantoprazole | 19 | $307 | $16 |
| Lovastatin | 11 | $259 | $24 |
| Ramipril | 16 | $187 | $12 |
2022: 55 drugs
| Eliquis | 539 | $723,155 | $1,342 |
| Xarelto | 97 | $140,845 | $1,452 |
| Repatha Sureclick | 126 | $101,305 | $804 |
| Entresto | 55 | $90,766 | $1,650 |
| Brilinta | 37 | $33,175 | $897 |
| Livalo | 30 | $28,788 | $960 |
| Vascepa | 20 | $18,702 | $935 |
| Metoprolol | 762 | $15,867 | $21 |
| Flecainide Acetate | 136 | $11,056 | $81 |
| Ezetimibe | 99 | $8,764 | $89 |
| Diltiazem 24hr Er (Cd) | 102 | $7,925 | $78 |
| Atorvastatin | 520 | $7,555 | $15 |
| Nebivolol | 49 | $6,310 | $129 |
| Rosuvastatin | 205 | $6,142 | $30 |
| Bumetanide | 36 | $5,958 | $165 |
| Losartan | 457 | $5,544 | $12 |
| Amlodipine Besylate | 487 | $4,071 | $8 |
| Potassium Chloride | 69 | $3,239 | $47 |
| Bystolic | 12 | $2,715 | $226 |
| Midodrine | 14 | $2,620 | $187 |
| Losartan-Hydrochlorothiazide | 113 | $2,597 | $23 |
| Ranolazine Er | 11 | $2,310 | $210 |
| Furosemide | 287 | $2,147 | $7 |
| Clopidogrel | 99 | $2,121 | $21 |
| Propafenone Hcl Er | 12 | $1,939 | $162 |
| Metoprolol | 164 | $1,697 | $10 |
| Ezetimibe-Simvastatin | 12 | $1,605 | $134 |
| Sotalol Af | 19 | $1,579 | $83 |
| Carvedilol | 100 | $1,562 | $16 |
| Sotalol | 39 | $1,398 | $36 |
| Hydralazine | 35 | $1,315 | $38 |
| Digoxin | 28 | $1,145 | $41 |
| Lisinopril | 139 | $1,122 | $8 |
| Warfarin | 67 | $1,117 | $17 |
| Atenolol | 95 | $1,090 | $11 |
| Verapamil Er | 27 | $963 | $36 |
| Isosorbide Mononitrate Er | 55 | $947 | $17 |
| Fenofibrate | 18 | $928 | $52 |
| Hydrochlorothiazide | 224 | $920 | $4 |
| Simvastatin | 76 | $862 | $11 |
| Olmesartan Medoxomil | 24 | $603 | $25 |
| Pantoprazole | 21 | $565 | $27 |
| Valsartan-Hydrochlorothiazide | 12 | $459 | $38 |
| Klor-Con 10 | 11 | $451 | $41 |
| Pravastatin | 31 | $430 | $14 |
| Olmesartan-Hydrochlorothiazide | 11 | $416 | $38 |
| Spironolactone | 33 | $399 | $12 |
| Valsartan | 16 | $396 | $25 |
| Amiodarone | 21 | $396 | $19 |
| Benazepril | 25 | $322 | $13 |
| Enalapril Maleate | 21 | $292 | $14 |
| Felodipine Er | 11 | $222 | $20 |
| Quinapril | 11 | $217 | $20 |
| Triamterene-Hydrochlorothiazid | 17 | $209 | $12 |
| Ramipril | 15 | $187 | $12 |
2021: 54 drugs
| Eliquis | 582 | $651,352 | $1,119 |
| Xarelto | 105 | $140,666 | $1,340 |
| Entresto | 73 | $96,285 | $1,319 |
| Repatha Sureclick | 101 | $61,790 | $612 |
| Brilinta | 41 | $43,620 | $1,064 |
| Livalo | 33 | $26,370 | $799 |
| Vascepa | 36 | $20,827 | $579 |
| Metoprolol | 748 | $17,447 | $23 |
| Pradaxa | 11 | $15,968 | $1,452 |
| Flecainide Acetate | 157 | $15,712 | $100 |
| Bystolic | 38 | $14,892 | $392 |
| Atorvastatin | 521 | $8,972 | $17 |
| Rosuvastatin | 160 | $7,818 | $49 |
| Ezetimibe | 88 | $7,624 | $87 |
| Diltiazem 24hr Er (Cd) | 109 | $7,543 | $69 |
| Propafenone Hcl Er | 17 | $6,893 | $405 |
| Losartan | 405 | $6,345 | $16 |
| Ranolazine Er | 12 | $4,687 | $391 |
| Bumetanide | 34 | $4,152 | $122 |
| Amlodipine Besylate | 455 | $3,968 | $9 |
| Potassium Chloride | 88 | $3,722 | $42 |
| Midodrine | 33 | $2,570 | $78 |
| Clopidogrel | 123 | $2,426 | $20 |
| Furosemide | 261 | $2,230 | $9 |
| Sotalol Af | 19 | $2,058 | $108 |
| Metoprolol | 178 | $2,029 | $11 |
| Digoxin | 31 | $1,784 | $58 |
| Losartan-Hydrochlorothiazide | 65 | $1,649 | $25 |
| Carvedilol | 117 | $1,608 | $14 |
| Warfarin | 87 | $1,392 | $16 |
| Lisinopril | 142 | $1,353 | $10 |
| Fenofibrate | 21 | $1,335 | $64 |
| Dilt-Xr | 14 | $1,284 | $92 |
| Hydrochlorothiazide | 210 | $1,199 | $6 |
| Sotalol | 33 | $1,097 | $33 |
| Isosorbide Mononitrate Er | 48 | $1,090 | $23 |
| Atenolol | 80 | $967 | $12 |
| Simvastatin | 93 | $935 | $10 |
| Hydralazine | 28 | $922 | $33 |
| Pravastatin | 42 | $857 | $20 |
| Olmesartan Medoxomil | 19 | $795 | $42 |
| Valsartan-Hydrochlorothiazide | 11 | $665 | $60 |
| Irbesartan | 15 | $649 | $43 |
| Pantoprazole | 30 | $596 | $20 |
| Verapamil Er | 16 | $575 | $36 |
| Enalapril Maleate | 25 | $396 | $16 |
| Ramipril | 20 | $377 | $19 |
| Valsartan | 16 | $377 | $24 |
| Klor-Con 10 | 19 | $364 | $19 |
| Triamterene-Hydrochlorothiazid | 21 | $336 | $16 |
| Benazepril | 30 | $320 | $11 |
| Spironolactone | 24 | $297 | $12 |
| Omeprazole | 12 | $230 | $19 |
| Jantoven | 11 | $156 | $14 |
2020: 59 drugs
| Eliquis | 588 | $590,001 | $1,003 |
| Xarelto | 80 | $96,906 | $1,211 |
| Entresto | 55 | $61,360 | $1,116 |
| Brilinta | 48 | $43,299 | $902 |
| Repatha Sureclick | 78 | $42,615 | $546 |
| Livalo | 42 | $30,430 | $725 |
| Metoprolol | 683 | $19,179 | $28 |
| Flecainide Acetate | 174 | $17,723 | $102 |
| Pradaxa | 13 | $16,835 | $1,295 |
| Bystolic | 45 | $16,612 | $369 |
| Vascepa | 39 | $16,585 | $425 |
| Diltiazem 24hr Er (Cd) | 127 | $9,875 | $78 |
| Atorvastatin | 516 | $9,287 | $18 |
| Ezetimibe | 100 | $8,436 | $84 |
| Rosuvastatin | 128 | $6,612 | $52 |
| Losartan | 382 | $6,308 | $17 |
| Bumetanide | 34 | $4,387 | $129 |
| Losartan-Hydrochlorothiazide | 59 | $3,853 | $65 |
| Potassium Chloride | 83 | $3,796 | $46 |
| Amlodipine Besylate | 435 | $3,338 | $8 |
| Furosemide | 239 | $2,194 | $9 |
| Digoxin | 42 | $2,056 | $49 |
| Clopidogrel | 127 | $2,032 | $16 |
| Midodrine | 21 | $1,946 | $93 |
| Metoprolol | 207 | $1,927 | $9 |
| Dilt-Xr | 30 | $1,773 | $59 |
| Fenofibrate | 21 | $1,736 | $83 |
| Sotalol | 40 | $1,711 | $43 |
| Hydrochlorothiazide | 253 | $1,647 | $7 |
| Lisinopril | 154 | $1,605 | $10 |
| Carvedilol | 129 | $1,587 | $12 |
| Diltiazem 24hr Er | 24 | $1,550 | $65 |
| Warfarin | 91 | $1,369 | $15 |
| Propafenone | 15 | $1,209 | $81 |
| Atenolol | 91 | $1,164 | $13 |
| Klor-Con 10 | 25 | $1,089 | $44 |
| Sotalol Af | 16 | $1,070 | $67 |
| Pravastatin | 38 | $1,049 | $28 |
| Valsartan-Hydrochlorothiazide | 12 | $1,044 | $87 |
| Simvastatin | 100 | $1,033 | $10 |
| Isosorbide Mononitrate Er | 35 | $969 | $28 |
| Olmesartan Medoxomil | 27 | $908 | $34 |
| Valsartan | 22 | $902 | $41 |
| Hydralazine | 29 | $897 | $31 |
| Benazepril-Hydrochlorothiazide | 11 | $772 | $70 |
| Metolazone | 18 | $678 | $38 |
| Amiodarone | 16 | $678 | $42 |
| Enalapril Maleate | 21 | $566 | $27 |
| Ramipril | 27 | $507 | $19 |
| Irbesartan | 11 | $476 | $43 |
| Verapamil Er | 14 | $451 | $32 |
| Triamterene-Hydrochlorothiazid | 25 | $431 | $17 |
| Spironolactone | 28 | $342 | $12 |
| Benazepril | 27 | $312 | $12 |
| Omeprazole | 13 | $292 | $22 |
| Pantoprazole | 21 | $243 | $12 |
| Nitroglycerin | 12 | $210 | $18 |
| Famotidine | 11 | $207 | $19 |
| Gabapentin | 11 | $123 | $11 |
2019: 59 drugs
| Eliquis | 523 | $486,006 | $929 |
| Xarelto | 66 | $70,005 | $1,061 |
| Brilinta | 65 | $55,002 | $846 |
| Entresto | 32 | $33,925 | $1,060 |
| Livalo | 40 | $25,284 | $632 |
| Repatha Sureclick | 23 | $19,579 | $851 |
| Metoprolol | 599 | $18,908 | $32 |
| Bystolic | 49 | $17,681 | $361 |
| Praluent | 24 | $17,323 | $722 |
| Pradaxa | 16 | $15,922 | $995 |
| Vascepa | 35 | $14,436 | $412 |
| Flecainide Acetate | 141 | $11,315 | $80 |
| Atorvastatin | 471 | $8,977 | $19 |
| Diltiazem 24hr Er (Cd) | 93 | $7,796 | $84 |
| Rosuvastatin | 97 | $7,024 | $72 |
| Ezetimibe | 77 | $6,967 | $90 |
| Losartan | 323 | $4,671 | $14 |
| Amlodipine Besylate | 389 | $3,768 | $10 |
| Coumadin | 15 | $3,051 | $203 |
| Potassium Chloride | 52 | $3,028 | $58 |
| Clopidogrel | 145 | $2,892 | $20 |
| Bumetanide | 20 | $2,802 | $140 |
| Warfarin | 109 | $2,409 | $22 |
| Metoprolol | 215 | $2,051 | $10 |
| Omega-3 Acid Ethyl Esters | 18 | $1,997 | $111 |
| Diltiazem 24hr Er | 27 | $1,914 | $71 |
| Digoxin | 34 | $1,827 | $54 |
| Carvedilol | 126 | $1,822 | $14 |
| Furosemide | 210 | $1,791 | $9 |
| Sotalol | 43 | $1,724 | $40 |
| Losartan-Hydrochlorothiazide | 101 | $1,631 | $16 |
| Dilt-Xr | 26 | $1,592 | $61 |
| Hydrochlorothiazide | 213 | $1,531 | $7 |
| Lisinopril | 154 | $1,506 | $10 |
| Fenofibrate | 24 | $1,377 | $57 |
| Isosorbide Mononitrate Er | 56 | $1,367 | $24 |
| Simvastatin | 99 | $1,076 | $11 |
| Pravastatin | 28 | $969 | $35 |
| Cartia Xt | 17 | $920 | $54 |
| Atenolol | 87 | $912 | $10 |
| Benazepril-Hydrochlorothiazide | 12 | $887 | $74 |
| Toprol Xl | 15 | $860 | $57 |
| Olmesartan Medoxomil | 21 | $776 | $37 |
| Sotalol Af | 13 | $744 | $57 |
| Enalapril Maleate | 20 | $736 | $37 |
| Olmesartan-Hydrochlorothiazide | 16 | $726 | $45 |
| Verapamil Er | 18 | $685 | $38 |
| Valsartan | 15 | $524 | $35 |
| Hydralazine | 20 | $511 | $26 |
| Irbesartan | 12 | $507 | $42 |
| Digitek | 16 | $381 | $24 |
| Benazepril | 30 | $381 | $13 |
| Triamterene-Hydrochlorothiazid | 26 | $323 | $12 |
| Pantoprazole | 25 | $321 | $13 |
| Spironolactone | 21 | $302 | $14 |
| Ramipril | 25 | $287 | $11 |
| Ranitidine | 12 | $270 | $22 |
| Gabapentin | 20 | $197 | $10 |
| Lovastatin | 13 | $69 | $5 |
2018: 59 drugs
| Eliquis | 416 | $321,109 | $772 |
| Xarelto | 60 | $51,984 | $866 |
| Brilinta | 53 | $31,455 | $593 |
| Bystolic | 53 | $22,010 | $415 |
| Livalo | 35 | $21,153 | $604 |
| Metoprolol | 557 | $19,114 | $34 |
| Repatha Sureclick | 12 | $16,067 | $1,339 |
| Entresto | 23 | $15,184 | $660 |
| Pradaxa | 15 | $12,173 | $812 |
| Ranexa | 16 | $9,940 | $621 |
| Ezetimibe | 52 | $9,914 | $191 |
| Flecainide Acetate | 145 | $8,792 | $61 |
| Atorvastatin | 415 | $8,716 | $21 |
| Vascepa | 20 | $8,003 | $400 |
| Rosuvastatin | 81 | $5,162 | $64 |
| Lipitor | 12 | $5,040 | $420 |
| Coumadin | 33 | $5,019 | $152 |
| Diltiazem 24hr Er (Cd) | 87 | $4,407 | $51 |
| Amlodipine Besylate | 393 | $3,823 | $10 |
| Olmesartan Medoxomil | 15 | $3,710 | $247 |
| Losartan | 285 | $3,442 | $12 |
| Warfarin | 140 | $2,947 | $21 |
| Clopidogrel | 146 | $2,877 | $20 |
| Fenofibrate | 26 | $2,198 | $85 |
| Metoprolol | 229 | $2,087 | $9 |
| Cartia Xt | 38 | $2,042 | $54 |
| Potassium Chloride | 51 | $1,836 | $36 |
| Digox | 26 | $1,779 | $68 |
| Olmesartan-Hydrochlorothiazide | 21 | $1,751 | $83 |
| Furosemide | 212 | $1,719 | $8 |
| Carvedilol | 158 | $1,687 | $11 |
| Sotalol | 59 | $1,644 | $28 |
| Isosorbide Mononitrate Er | 71 | $1,567 | $22 |
| Hydrochlorothiazide | 215 | $1,545 | $7 |
| Valsartan | 22 | $1,537 | $70 |
| Diltiazem 24hr Er | 29 | $1,400 | $48 |
| Digoxin | 32 | $1,336 | $42 |
| Propranolol Hcl Er | 21 | $1,295 | $62 |
| Lisinopril | 136 | $1,193 | $9 |
| Pravastatin | 34 | $1,069 | $31 |
| Losartan-Hydrochlorothiazide | 93 | $1,065 | $11 |
| Atenolol | 79 | $1,032 | $13 |
| Sotalol Af | 11 | $1,015 | $92 |
| Toprol Xl | 16 | $981 | $61 |
| Fenofibric Acid | 11 | $966 | $88 |
| Simvastatin | 94 | $916 | $10 |
| Valsartan-Hydrochlorothiazide | 24 | $841 | $35 |
| Verapamil Er | 26 | $780 | $30 |
| Dilt-Xr | 12 | $651 | $54 |
| Enalapril Maleate | 17 | $625 | $37 |
| Digitek | 20 | $558 | $28 |
| Benazepril | 30 | $459 | $15 |
| Spironolactone | 22 | $390 | $18 |
| Hydralazine | 16 | $351 | $22 |
| Pantoprazole | 30 | $337 | $11 |
| Ramipril | 26 | $327 | $13 |
| Nitroglycerin | 12 | $290 | $24 |
| Triamterene-Hydrochlorothiazid | 17 | $173 | $10 |
| Gabapentin | 18 | $116 | $6 |
2017: 61 drugs
| Eliquis | 410 | $248,130 | $605 |
| Xarelto | 55 | $36,502 | $664 |
| Bystolic | 89 | $25,778 | $290 |
| Brilinta | 39 | $25,127 | $644 |
| Metoprolol | 558 | $17,011 | $30 |
| Zetia | 19 | $16,356 | $861 |
| Ranexa | 36 | $15,360 | $427 |
| Pradaxa | 24 | $14,587 | $608 |
| Livalo | 40 | $13,843 | $346 |
| Atorvastatin | 446 | $7,736 | $17 |
| Ezetimibe | 22 | $7,286 | $331 |
| Olmesartan Medoxomil | 19 | $7,032 | $370 |
| Vascepa | 30 | $6,998 | $233 |
| Rosuvastatin | 81 | $6,852 | $85 |
| Savaysa | 13 | $6,286 | $484 |
| Flecainide Acetate | 111 | $5,560 | $50 |
| Entresto | 12 | $4,995 | $416 |
| Lipitor | 12 | $4,469 | $372 |
| Warfarin | 247 | $4,435 | $18 |
| Diltiazem 24hr Er | 133 | $4,099 | $31 |
| Coumadin | 20 | $3,881 | $194 |
| Clopidogrel | 190 | $3,157 | $17 |
| Amlodipine Besylate | 435 | $2,982 | $7 |
| Losartan | 273 | $2,980 | $11 |
| Olmesartan-Hydrochlorothiazide | 14 | $2,865 | $205 |
| Digox | 31 | $2,087 | $67 |
| Potassium Chloride | 56 | $2,045 | $37 |
| Metoprolol | 251 | $1,915 | $8 |
| Carvedilol | 208 | $1,795 | $9 |
| Propranolol Hcl Er | 20 | $1,779 | $89 |
| Furosemide | 270 | $1,624 | $6 |
| Cartia Xt | 51 | $1,623 | $32 |
| Fenofibrate | 24 | $1,504 | $63 |
| Digoxin | 32 | $1,492 | $47 |
| Hydrochlorothiazide | 223 | $1,442 | $6 |
| Bumetanide | 16 | $1,357 | $85 |
| Isosorbide Mononitrate Er | 73 | $1,311 | $18 |
| Valsartan-Hydrochlorothiazide | 30 | $1,278 | $43 |
| Lisinopril | 149 | $1,237 | $8 |
| Sotalol | 53 | $1,144 | $22 |
| Pravastatin | 40 | $1,059 | $26 |
| Simvastatin | 118 | $983 | $8 |
| Valsartan | 47 | $949 | $20 |
| Verapamil Sr | 14 | $941 | $67 |
| Omega-3 Acid Ethyl Esters | 11 | $911 | $83 |
| Enalapril Maleate | 21 | $869 | $41 |
| Atenolol | 92 | $607 | $7 |
| Ramipril | 28 | $535 | $19 |
| Losartan-Hydrochlorothiazide | 33 | $458 | $14 |
| Telmisartan | 13 | $448 | $34 |
| Hydralazine | 27 | $429 | $16 |
| Verapamil Er | 18 | $426 | $24 |
| Pantoprazole | 42 | $423 | $10 |
| Digitek | 13 | $389 | $30 |
| Benazepril | 25 | $352 | $14 |
| Triamterene-Hydrochlorothiazid | 30 | $331 | $11 |
| Spironolactone | 27 | $304 | $11 |
| Amiodarone | 17 | $251 | $15 |
| Nitroglycerin | 14 | $247 | $18 |
| Lovastatin | 11 | $62 | $6 |
| Gabapentin | 12 | $61 | $5 |
2016: 64 drugs
| Eliquis | 340 | $195,862 | $576 |
| Crestor | 56 | $27,257 | $487 |
| Bystolic | 90 | $23,315 | $259 |
| Brilinta | 36 | $18,449 | $512 |
| Xarelto | 32 | $16,905 | $528 |
| Vytorin | 32 | $15,500 | $484 |
| Pradaxa | 24 | $15,088 | $629 |
| Zetia | 24 | $14,229 | $593 |
| Metoprolol | 527 | $12,591 | $24 |
| Benicar | 38 | $12,537 | $330 |
| Livalo | 35 | $11,196 | $320 |
| Ranexa | 31 | $8,630 | $278 |
| Atorvastatin | 433 | $7,575 | $17 |
| Vascepa | 28 | $5,421 | $194 |
| Diltiazem 24hr Er | 152 | $5,078 | $33 |
| Flecainide Acetate | 121 | $4,316 | $36 |
| Lipitor | 12 | $3,820 | $318 |
| Warfarin | 241 | $3,779 | $16 |
| Rosuvastatin | 33 | $3,191 | $97 |
| Coumadin | 19 | $3,108 | $164 |
| Clopidogrel | 170 | $2,879 | $17 |
| Amlodipine Besylate | 448 | $2,602 | $6 |
| Digoxin | 59 | $2,467 | $42 |
| Tenormin | 12 | $2,295 | $191 |
| Losartan | 284 | $2,256 | $8 |
| Carvedilol | 213 | $2,085 | $10 |
| Valsartan | 46 | $2,064 | $45 |
| Diltiazem 24hr Cd | 16 | $1,940 | $121 |
| Niacin Er | 14 | $1,871 | $134 |
| Esomeprazole Magnesium | 12 | $1,811 | $151 |
| Fenofibrate | 26 | $1,649 | $63 |
| Metoprolol | 231 | $1,644 | $7 |
| Potassium Chloride | 33 | $1,518 | $46 |
| Propranolol Hcl Er | 11 | $1,496 | $136 |
| Lisinopril | 167 | $1,477 | $9 |
| Isosorbide Mononitrate Er | 73 | $1,304 | $18 |
| Cartia Xt | 27 | $1,212 | $45 |
| Bumetanide | 28 | $1,174 | $42 |
| Hydrochlorothiazide | 258 | $1,157 | $4 |
| Amiodarone | 42 | $1,129 | $27 |
| Ramipril | 29 | $1,104 | $38 |
| Furosemide | 222 | $1,068 | $5 |
| Pravastatin | 41 | $1,065 | $26 |
| Enalapril Maleate | 29 | $1,021 | $35 |
| Taztia Xt | 20 | $1,000 | $50 |
| Valsartan-Hydrochlorothiazide | 28 | $995 | $36 |
| Digox | 22 | $923 | $42 |
| Simvastatin | 104 | $918 | $9 |
| Cozaar | 12 | $889 | $74 |
| Verapamil Sr | 13 | $882 | $68 |
| Sotalol | 34 | $761 | $22 |
| Nitrostat | 18 | $640 | $36 |
| Hydralazine | 36 | $546 | $15 |
| Spironolactone | 44 | $526 | $12 |
| Atenolol | 82 | $471 | $6 |
| Diltiazem Er | 11 | $452 | $41 |
| Verapamil Er | 18 | $386 | $21 |
| Metolazone | 13 | $381 | $29 |
| Benazepril | 29 | $379 | $13 |
| Losartan-Hydrochlorothiazide | 40 | $338 | $8 |
| Temazepam | 11 | $310 | $28 |
| Triamterene-Hydrochlorothiazid | 32 | $280 | $9 |
| Digitek | 11 | $254 | $23 |
| Pantoprazole | 30 | $206 | $7 |
2015: 48 drugs
| Eliquis | 155 | $101,153 | $653 |
| Brilinta | 35 | $13,937 | $398 |
| Pradaxa | 20 | $10,806 | $540 |
| Metoprolol | 319 | $10,424 | $33 |
| Livalo | 34 | $9,804 | $288 |
| Bystolic | 38 | $9,154 | $241 |
| Benicar | 35 | $8,354 | $239 |
| Crestor | 28 | $7,704 | $275 |
| Ranexa | 21 | $6,877 | $327 |
| Vytorin | 16 | $4,779 | $299 |
| Atorvastatin | 284 | $4,324 | $15 |
| Warfarin | 182 | $3,016 | $17 |
| Esomeprazole Magnesium | 15 | $2,942 | $196 |
| Clopidogrel | 217 | $2,836 | $13 |
| Flecainide Acetate | 71 | $2,315 | $33 |
| Diltiazem 24hr Cd | 24 | $2,290 | $95 |
| Coumadin | 16 | $2,026 | $127 |
| Diltiazem 24hr Er | 74 | $1,957 | $26 |
| Digoxin | 40 | $1,799 | $45 |
| Amlodipine Besylate | 273 | $1,691 | $6 |
| Losartan | 218 | $1,591 | $7 |
| Cartia Xt | 40 | $1,277 | $32 |
| Metoprolol | 189 | $1,205 | $6 |
| Hydrochlorothiazide | 204 | $1,132 | $6 |
| Valsartan | 22 | $1,110 | $50 |
| Valsartan-Hydrochlorothiazide | 30 | $1,098 | $37 |
| Pravastatin | 25 | $1,033 | $41 |
| Diltiazem Er | 22 | $994 | $45 |
| Isosorbide Mononitrate Er | 60 | $987 | $16 |
| Carvedilol | 109 | $942 | $9 |
| Amiodarone | 19 | $932 | $49 |
| Digox | 19 | $914 | $48 |
| Lisinopril | 139 | $804 | $6 |
| Potassium Chloride | 27 | $717 | $27 |
| Furosemide | 143 | $689 | $5 |
| Quinapril | 18 | $669 | $37 |
| Simvastatin | 78 | $559 | $7 |
| Hydralazine | 44 | $485 | $11 |
| Enalapril Maleate | 19 | $481 | $25 |
| Sotalol | 24 | $450 | $19 |
| Bumetanide | 18 | $439 | $24 |
| Triamterene-Hydrochlorothiazid | 26 | $305 | $12 |
| Atenolol | 66 | $296 | $4 |
| Pantoprazole | 30 | $278 | $9 |
| Verapamil Er | 17 | $247 | $15 |
| Benazepril | 25 | $215 | $9 |
| Spironolactone | 24 | $166 | $7 |
| Losartan-Hydrochlorothiazide | 18 | $114 | $6 |
2014: 49 drugs
| Eliquis | 92 | $42,845 | $466 |
| Pradaxa | 27 | $13,214 | $489 |
| Effient | 32 | $10,863 | $339 |
| Metoprolol | 256 | $9,886 | $39 |
| Brilinta | 20 | $6,459 | $323 |
| Diovan | 26 | $5,932 | $228 |
| Benicar | 29 | $5,927 | $204 |
| Clopidogrel | 240 | $5,209 | $22 |
| Ranexa | 14 | $5,166 | $369 |
| Crestor | 27 | $5,110 | $189 |
| Nexium | 15 | $4,581 | $305 |
| Atorvastatin | 215 | $3,635 | $17 |
| Livalo | 18 | $3,613 | $201 |
| Bystolic | 27 | $3,481 | $129 |
| Warfarin | 241 | $2,887 | $12 |
| Exforge | 12 | $2,251 | $188 |
| Valsartan | 15 | $2,167 | $144 |
| Diltiazem 24hr Er | 77 | $2,090 | $27 |
| Amlodipine Besylate | 201 | $1,801 | $9 |
| Coumadin | 18 | $1,781 | $99 |
| Losartan | 152 | $1,654 | $11 |
| Valsartan-Hydrochlorothiazide | 29 | $1,490 | $51 |
| Digoxin | 35 | $1,488 | $43 |
| Metoprolol | 175 | $1,435 | $8 |
| Carvedilol | 80 | $1,209 | $15 |
| Digox | 27 | $1,131 | $42 |
| Diltiazem Er | 29 | $1,119 | $39 |
| Diltiazem 24hr Cd | 22 | $901 | $41 |
| Hydrochlorothiazide | 128 | $896 | $7 |
| Pravastatin | 17 | $889 | $52 |
| Quinapril | 16 | $883 | $55 |
| Lisinopril | 107 | $843 | $8 |
| Simvastatin | 68 | $705 | $10 |
| Cartia Xt | 17 | $691 | $41 |
| Potassium Chloride | 20 | $592 | $30 |
| Furosemide | 141 | $545 | $4 |
| Isosorbide Mononitrate Er | 33 | $543 | $16 |
| Atenolol | 92 | $522 | $6 |
| Sotalol | 14 | $422 | $30 |
| Flecainide Acetate | 11 | $401 | $36 |
| Enalapril Maleate | 30 | $398 | $13 |
| Pantoprazole | 24 | $333 | $14 |
| Lovastatin | 19 | $300 | $16 |
| Triamterene-Hydrochlorothiazid | 21 | $280 | $13 |
| Terazosin | 11 | $240 | $22 |
| Verapamil Er | 14 | $222 | $16 |
| Amiodarone | 13 | $183 | $14 |
| Benazepril | 12 | $138 | $12 |
| Spironolactone | 11 | $128 | $12 |
2013: 21 drugs
| Clopidogrel | 126 | $7,891 | $63 |
| Effient | 17 | $7,587 | $446 |
| Eliquis | 19 | $6,037 | $318 |
| Metoprolol | 57 | $2,973 | $52 |
| Atorvastatin | 57 | $2,439 | $43 |
| Bystolic | 12 | $1,362 | $113 |
| Amlodipine Besylate | 90 | $965 | $11 |
| Losartan | 55 | $938 | $17 |
| Warfarin | 70 | $852 | $12 |
| Diltiazem 24hr Er | 20 | $704 | $35 |
| Metoprolol | 59 | $575 | $10 |
| Carvedilol | 28 | $547 | $20 |
| Lisinopril | 42 | $535 | $13 |
| Simvastatin | 34 | $526 | $15 |
| Pantoprazole | 15 | $449 | $30 |
| Hydrochlorothiazide | 56 | $430 | $8 |
| Isosorbide Mononitrate Er | 11 | $304 | $28 |
| Furosemide | 42 | $243 | $6 |
| Digoxin | 11 | $217 | $20 |
| Atenolol | 23 | $189 | $8 |
| Famotidine | 13 | $113 | $9 |
Money from drug and device companies
$5,738 in 2025
| 2025 | 28 | 155 | None | $5,738 |
| 2024 | 28 | 160 | $1,786 | $8,237 |
| 2023 | 29 | 168 | $613 | $8,578 |
| 2022 | 26 | 143 | $6,000 | $12,210 |
| 2021 | 25 | 172 | $5,700 | $12,347 |
| 2020 | 21 | 143 | $3,734 | $8,137 |
| 2019 | 29 | 212 | $25,217 | $35,359 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Philips North America | Coronary Other | $1,709 | 16 payments
|
| Shockwave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $504 | 15 payments
|
| Novartis Pharmaceuticals | Leqvio | $504 | 22 payments
|
| Cordis US | Mynx Control Venous | $331 | 3 payments
|
| Abbott Laboratories | Cardiomems | $327 | 5 payments
|
| Heartflow | Ffrct | $249 | 4 payments
|
See all 155 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-16 | Jardiance | $30 |
| AGEPHA Pharma FZ | Meals · 2025-12-15 | Lodoco | $28 |
| Biosense Webster | Meals · 2025-12-12 | Carto 3 | $147 |
| Amgen | Meals · 2025-12-12 | Repatha | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-11 | Eliquis | $7 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-10 | Eliquis | $11 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-09 | Eliquis | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-08 | Kerendia | $22 |
| Pfizer | Meals · 2025-12-05 | Eliquis | $20 |
| Esperion Therapeutics | Meals · 2025-12-05 | Nexletol | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-24 | Eliquis | $6 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-24 | Eliquis | $13 |
| Merck Sharp & Dohme | Meals · 2025-11-21 | Capvaxive | $25 |
| Philips North America | Meals · 2025-11-20 | Coronary Other | $88 |
| Pfizer | Meals · 2025-11-19 | Eliquis | $16 |
| AtriCure | Meals · 2025-11-17 | Epi-Sense Guided Coagulation System With Visitrax | $26 |
| Esperion Therapeutics | Meals · 2025-11-14 | Nexletol | $18 |
| Shockwave Medical | Meals · 2025-11-13 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $5 |
| Novo Nordisk | Meals · 2025-11-13 | Wegovy | $13 |
| Novartis Pharmaceuticals | Meals · 2025-11-11 | Leqvio | $31 |
| Abbott Laboratories | Meals · 2025-11-11 | Amplatzer Amulet | $14 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-10 | Kerendia | $21 |
| Cardiva Medical | Meals · 2025-11-07 | Cardiva Vascade Mvp Xl Vvcs 10-12f | $29 |
| Novartis Pharmaceuticals | Meals · 2025-11-05 | Leqvio | $141 |
| Cordis US | Meals · 2025-10-29 | Mynx Control Venous | $283 |
| Philips North America | Meals · 2025-10-28 | Igt Devices Systems Undivided | $115 |
| Philips North America | Meals · 2025-10-28 | Coronary Other | $37 |
| Cordis US | Meals · 2025-10-28 | Mynx Control Venous | $30 |
| Shockwave Medical | Meals · 2025-10-27 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $90 |
| Philips North America | Meals · 2025-10-27 | Coronary Other | $56 |
| Philips North America | Meals · 2025-10-27 | Coronary Other | $131 |
| Shockwave Medical | Meals · 2025-10-26 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $58 |
| Shockwave Medical | Meals · 2025-10-25 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $79 |
| Abbott Laboratories | Meals · 2025-10-24 | Cardiomems | $124 |
| Lilly USA | Meals · 2025-10-16 | Mounjaro | $18 |
| Philips North America | Meals · 2025-10-13 | Coronary Other | $75 |
| Novartis Pharmaceuticals | Meals · 2025-10-10 | Leqvio | $10 |
| Novo Nordisk | Meals · 2025-09-30 | Wegovy | $5 |
| Novo Nordisk | Meals · 2025-09-30 | Wegovy | $5 |
| Pfizer | Meals · 2025-09-26 | Eliquis | $14 |
| Novo Nordisk | Meals · 2025-09-25 | Wegovy | $21 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-09-24 | Lifevest | $12 |
| Boston Scientific | Meals · 2025-09-24 | Watchman Flx | $132 |
| Merck Sharp & Dohme | Meals · 2025-09-23 | Verquvo | $23 |
| Shockwave Medical | Meals · 2025-09-22 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $20 |
| Shockwave Medical | Meals · 2025-09-22 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $6 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-18 | Eliquis | $7 |
| Biotronik | Meals · 2025-09-18 | Amvia Edge | $167 |
| Shockwave Medical | Meals · 2025-09-17 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $45 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-17 | Kerendia | $23 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-09-16 | Lifevest | $22 |
| Novartis Pharmaceuticals | Meals · 2025-09-16 | Leqvio | $9 |
| Shockwave Medical | Meals · 2025-09-11 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-09 | Eliquis | $21 |
| Novartis Pharmaceuticals | Meals · 2025-09-02 | Leqvio | $9 |
| Novartis Pharmaceuticals | Meals · 2025-09-02 | Leqvio | $9 |
| Merck Sharp & Dohme | Meals · 2025-08-29 | Verquvo | $29 |
| Biotronik | Meals · 2025-08-28 | Amvia Edge | $15 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-27 | Kerendia | $22 |
| Bayer Healthcare Pharmaceuticals | Education · 2025-08-27 | Kerendia | $20 |
| Novartis Pharmaceuticals | Meals · 2025-08-26 | Leqvio | $4 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-26 | Jardiance | $15 |
| Shockwave Medical | Meals · 2025-08-25 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $23 |
| GlaxoSmithKline | Meals · 2025-08-22 | Shingrix | $20 |
| Pfizer | Meals · 2025-08-22 | Eliquis | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-21 | Farxiga | $22 |
| Shockwave Medical | Meals · 2025-08-20 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $19 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-08-18 | Lifevest | $17 |
| Novo Nordisk | Meals · 2025-08-10 | Wegovy | $21 |
| Baxter Healthcare | Meals · 2025-08-07 | Hillrom - Carnation Ambulatory Monitor | $33 |
| Novo Nordisk | Meals · 2025-08-07 | Wegovy | $22 |
| Novartis Pharmaceuticals | Meals · 2025-08-05 | Leqvio | $0 |
| Novartis Pharmaceuticals | Meals · 2025-08-05 | Leqvio | $19 |
| Shockwave Medical | Meals · 2025-08-02 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $31 |
| Pfizer | Meals · 2025-08-01 | Vyndaqel | $24 |
| Abiomed | Meals · 2025-07-30 | None | $37 |
| Boston Scientific | Meals · 2025-07-30 | Watchman Flx | $21 |
| Novartis Pharmaceuticals | Meals · 2025-07-28 | Leqvio | $7 |
| Novo Nordisk | Meals · 2025-07-26 | Wegovy | $21 |
| Pfizer | Meals · 2025-07-25 | Eliquis | $18 |
| Edwards Lifesciences | Meals · 2025-07-22 | Sapien 3 Ultra Resilia | $32 |
| Abbott Laboratories | Meals · 2025-07-15 | Cardiomems | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-10 | Eliquis | $9 |
| BridgeBio Pharma | Meals · 2025-07-09 | Attruby | $27 |
| Novartis Pharmaceuticals | Meals · 2025-07-08 | Leqvio | $4 |
| Heartflow | Meals · 2025-07-07 | Ffrct | $31 |
| Boston Scientific | Meals · 2025-07-02 | Watchman Flx | $18 |
| Merck Sharp & Dohme | Meals · 2025-07-01 | Verquvo | $31 |
| Novartis Pharmaceuticals | Meals · 2025-06-30 | Leqvio | $10 |
| Cordis US | Meals · 2025-06-23 | Mynx Control Venous | $18 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-06-20 | Lifevest | $12 |
| Biotronik | Meals · 2025-06-19 | Biomonitor | $15 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-16 | Kerendia | $33 |
| Boston Scientific | Meals · 2025-05-27 | Watchman Flx | $33 |
| Novo Nordisk | Meals · 2025-05-22 | Wegovy | $6 |
| Novo Nordisk | Meals · 2025-05-22 | Wegovy | $6 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-05-19 | Lifevest | $23 |
| Pfizer | Meals · 2025-05-16 | Eliquis | $15 |
| Novartis Pharmaceuticals | Meals · 2025-05-14 | Leqvio | $9 |
| Amgen | Meals · 2025-05-13 | Repatha | $24 |
| Merck Sharp & Dohme | Meals · 2025-05-12 | Verquvo | $26 |
| Novartis Pharmaceuticals | Meals · 2025-05-09 | Leqvio | $8 |
| Pfizer | Meals · 2025-05-09 | Vyndaqel | $22 |
| Novo Nordisk | Meals · 2025-05-02 | Wegovy | $10 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-29 | Jardiance | $21 |
| Philips North America | Travel · 2025-04-29 | Coronary Undivided | $426 |
| Novo Nordisk | Meals · 2025-04-28 | Wegovy | $21 |
| Abbott Laboratories | Meals · 2025-04-28 | Cardiomems | $146 |
| Philips North America | Meals · 2025-04-26 | Coronary Other | $5 |
| Philips North America | Meals · 2025-04-26 | Coronary Other | $140 |
| Philips North America | Meals · 2025-04-26 | Coronary Other | $147 |
| Philips North America | Meals · 2025-04-26 | Coronary Other | $36 |
| Pfizer | Meals · 2025-04-25 | Eliquis | $15 |
| Philips North America | Meals · 2025-04-25 | Coronary Other | $48 |
| Novartis Pharmaceuticals | Meals · 2025-04-24 | Leqvio | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-23 | Eliquis | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-23 | Eliquis | $2 |
| Amgen | Meals · 2025-04-22 | Repatha | $20 |
| Esperion Therapeutics | Meals · 2025-04-21 | Nexletol | $16 |
| Philips North America | Meals · 2025-04-16 | Coronary Undivided | $40 |
| Philips North America | Meals · 2025-04-15 | Coronary Undivided | $40 |
| Novartis Pharmaceuticals | Meals · 2025-04-08 | Leqvio | $10 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-02 | Eliquis | $20 |
| Novartis Pharmaceuticals | Meals · 2025-04-01 | Leqvio | $140 |
| Abbott Laboratories | Meals · 2025-03-27 | Cardiomems | $19 |
| Novo Nordisk | Meals · 2025-03-25 | Wegovy | $21 |
| Philips North America | Travel · 2025-03-25 | Coronary Other | $23 |
| Philips North America | Travel · 2025-03-25 | Coronary Other | $305 |
| Biotronik | Meals · 2025-03-24 | Renamic Neo | $6 |
| Shockwave Medical | Meals · 2025-03-19 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $17 |
| Heartflow | Meals · 2025-03-19 | Ffrct | $167 |
| Novo Nordisk | Meals · 2025-03-18 | Wegovy | $13 |
| Novartis Pharmaceuticals | Meals · 2025-03-18 | Leqvio | $8 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-18 | Farxiga | $20 |
| Pfizer | Meals · 2025-03-13 | Eliquis | $16 |
| Heartflow | Meals · 2025-03-13 | Ffrct | $21 |
| Amgen | Meals · 2025-03-07 | Repatha | $22 |
| Biotronik | Meals · 2025-03-06 | Biomonitor | $22 |
| Novartis Pharmaceuticals | Meals · 2025-03-04 | Leqvio | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-26 | Camzyos | $22 |
| Merck Sharp & Dohme | Meals · 2025-02-24 | Verquvo | $22 |
| Heartflow | Meals · 2025-02-18 | Ffrct | $31 |
| Pfizer | Meals · 2025-02-14 | Eliquis | $16 |
| Shockwave Medical | Meals · 2025-02-12 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $34 |
| Boston Scientific | Meals · 2025-02-11 | Watchman Flx | $19 |
| Novartis Pharmaceuticals | Meals · 2025-02-06 | Leqvio | $8 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-05 | Jardiance | $19 |
| Shockwave Medical | Meals · 2025-02-04 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $26 |
| Novartis Pharmaceuticals | Meals · 2025-02-04 | Leqvio | $8 |
| Shockwave Medical | Meals · 2025-01-28 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $27 |
| Biotronik | Meals · 2025-01-28 | Biomonitor | $12 |
| Novartis Pharmaceuticals | Meals · 2025-01-22 | Leqvio | $9 |
| Boston Scientific | Meals · 2025-01-15 | Watchman Flx | $14 |
| Esperion Therapeutics | Meals · 2025-01-13 | Nexletol | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-10 | Camzyos | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $8,237
| Abbott Laboratories | Cardiomems | $2,584 | 33 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $2,013 | 8 payments
|
| Novartis Pharmaceuticals | Leqvio | $596 | 28 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $470 | 12 payments
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $316 | 3 payments
|
| Merck Sharp & Dohme | Verquvo | $275 | 11 payments
|
| Amgen | Repatha | $194 | 12 payments
|
| Heartflow | Ffrct | $185 | 4 payments
|
| Recor Medical | Paradise Renal Denervation System | $183 | 1 payment
|
| Medtronic | Azure Xt Dr Mri Surescan | $173 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $153 | 1 payment
|
| Pfizer | Eliquis | $118 | 7 payments
|
| Asahi Intecc USA | Peripheral Vascular | $111 | 1 payment
|
| Philips North America | (Br0) Coronary Atherectomy | $104 | 2 payments
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $100 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $100 | 5 payments
|
| Sanofi-Aventis U.S. | Multaq | $86 | 3 payments
|
| Boston Scientific | Watchman Flx | $72 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $66 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $63 | 2 payments
|
| Novo Nordisk | Rybelsus | $59 | 3 payments
|
| Esperion Therapeutics | Nexletol | $53 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $45 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $44 | 2 payments
|
| Biotronik | None | $19 | 1 payment
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $19 | 1 payment
|
| Lexicon Pharmaceuticals | None | $19 | 1 payment
|
| Kestra Medical Technology Services | Assure Wcd | $17 | 1 payment
|
2023: $8,578
| Abbott Laboratories | Cardiomems | $1,892 | 20 payments
|
| Philips Electronics North America | (9266) Elca | $920 | 15 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $828 | 10 payments
|
| Inari Medical | Flowtriever Catheter, S | $642 | 7 payments
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $633 | 6 payments
|
| Boston Scientific | Watchman Flx | $443 | 9 payments
|
| Novartis Pharmaceuticals | Leqvio | $389 | 15 payments
|
| Penumbra | Indigo System | $356 | 3 payments
|
| Merck Sharp & Dohme | Verquvo | $341 | 13 payments
|
| Biotronik | Biomonitor | $257 | 2 payments
|
| Amgen | Repatha | $241 | 11 payments
|
| Janssen Pharmaceuticals | Xarelto | $233 | 10 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $227 | 4 payments
|
| AngioDynamics | Bioflo | $165 | 4 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $154 | 6 payments
|
| Pfizer | Eliquis | $151 | 9 payments
|
| Philips North America | (6574) Coronary Other | $140 | 1 payment
|
| Esperion Therapeutics | Nexletol | $111 | 5 payments
|
| Atricure | Atriclip Laa Exclusion System | $103 | 3 payments
|
| Asahi Intecc USA | Asahi Ptca Guide Wire | $64 | 1 payment
|
| Terumo Medical | Angio-Seal | $63 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $57 | 3 payments
|
| Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor | $32 | 2 payments
|
| Regeneron Healthcare Solutions | Evkeeza | $29 | 2 payments
|
| Lexicon Pharmaceuticals | Inpefa | $28 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $23 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $22 | 1 payment
|
| Medtronic | Corevalve Evolut R | $20 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $14 | 1 payment
|
2022: $12,210
| E.R. Squibb & Sons L.L.C. | Eliquis | $3,525 | 13 payments
|
| Amgen | Repatha | $3,273 | 10 payments
|
| Abbott Laboratories | Cardiomems | $1,295 | 20 payments
|
| Philips Electronics North America | (6574) Coronary Other | $815 | 7 payments
|
| Inari Medical | Flowtriever Catheter, S | $538 | 5 payments
|
| Biotronik | Biomonitor | $497 | 8 payments
|
| Boston Scientific | General - Therapies | $318 | 3 payments
|
| Bard Peripheral Vascular | Lutonix Drug Coated Balloon | $224 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $224 | 12 payments
|
| Janssen Pharmaceuticals | Xarelto | $197 | 10 payments
|
| Shockwave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $175 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $173 | 12 payments
|
| Actelion Pharmaceuticals US | Opsumit | $149 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $148 | 9 payments
|
| Abiomed | Impella | $148 | 1 payment
|
| Pfizer | Eliquis | $125 | 7 payments
|
| Esperion Therapeutics | Nexletol | $110 | 5 payments
|
| Alnylam Pharmaceuticals | Onpattro | $52 | 2 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $46 | 2 payments
|
| iRhythm Technologies | Zio Xt Patch | $38 | 2 payments
|
| Penumbra | Penumbra System | $32 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $31 | 1 payment
|
| Astellas Pharma US | Lexiscan | $23 | 1 payment
|
| Cardiovascular Systems | Diamondback Peripheral | $23 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $18 | 1 payment
|
| Medtronic | Linq II | $13 | 1 payment
|
2021: $12,347
| E.R. Squibb & Sons L.L.C. | Eliquis | $3,462 | 7 payments
|
| Amgen | Repatha | $3,184 | 12 payments
|
| Abbott Laboratories | Cardiomems Hf System | $1,686 | 26 payments
|
| Boston Scientific | General Vascular Access | $679 | 7 payments
|
| Biotronik | Biomonitor | $628 | 10 payments
|
| Medtronic | Corevalve Evolut | $555 | 6 payments
|
| Penumbra | Indigo System | $364 | 4 payments
|
| Philips Electronics North America | (8333) Igt D Coronary | $245 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $199 | 15 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $174 | 10 payments
|
| Novartis Pharmaceuticals | Entresto | $174 | 11 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $165 | 6 payments
|
| Kowa Pharmaceuticals America | Livalo | $157 | 10 payments
|
| Amarin Pharma | Vascepa | $144 | 8 payments
|
| Merck Sharp & Dohme | Verquvo | $142 | 7 payments
|
| Actelion Pharmaceuticals US | Uptravi | $103 | 5 payments
|
| Pfizer | Eliquis | $72 | 4 payments
|
| Sanofi-Aventis U.S. | Multaq | $65 | 4 payments
|
| Kiniksa Pharmaceuticals | None | $36 | 2 payments
|
| Esperion Therapeutics | Nexletol | $23 | 2 payments
|
| Lundbeck | Northera | $23 | 1 payment
|
| HeartFlow | Ffrct | $20 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $19 | 1 payment
|
| Ethicon US | Stratafix | $16 | 1 payment
|
| Astellas Pharma US | Lexiscan | $12 | 1 payment
|
2020: $8,137
| Amgen | Repatha | $4,345 | 20 payments
|
| Cardiovascular Systems | Coronary Orbital Atherectomy System | $629 | 5 payments
|
| Boston Scientific | Synergy | $447 | 7 payments
|
| Abbott Laboratories | Cardiomems Hf System | $432 | 5 payments
|
| Amarin Pharma | Vascepa | $254 | 13 payments
|
| Medtronic Vascular | Micra | $248 | 4 payments
|
| Biotronik | None | $243 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $193 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $178 | 9 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $152 | 7 payments
|
| Philips Electronics North America | Igt D Coronary | $149 | 3 payments
|
| Medicure Pharma | Hmg-Coa Reductase Inhibitor. | $136 | 1 payment
|
| Shockwave Medical | Vascular Lithotripsy | $131 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $119 | 10 payments
|
| Esperion Therapeutics | Nexletol | $117 | 12 payments
|
| Kowa Pharmaceuticals America | Livalo | $93 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $82 | 4 payments
|
| Lundbeck | Northera | $81 | 4 payments
|
| Pfizer | Chantix | $52 | 3 payments
|
| Sanofi-Aventis U.S. | Multaq | $40 | 2 payments
|
| Regeneron Healthcare Solutions | Praluent | $17 | 1 payment
|
2019: $35,359
| Amgen | Repatha | $15,656 | 27 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $5,954 | 15 payments
|
| Pfizer | Eliquis | $5,759 | 20 payments
|
| Cardiovascular Systems | Coronary Orbital Atherectomy System | $2,648 | 21 payments
|
| Biotronik | None | $1,447 | 14 payments
|
| Abbott Laboratories | Cardiomems Hf System | $813 | 10 payments
|
| Philips Electronics North America | Igt D Coronary | $552 | 7 payments
|
| Novartis Pharmaceuticals | Entresto | $341 | 17 payments
|
| Medtronic Vascular | 3f | $315 | 7 payments
|
| Boston Scientific | General - Stents | $251 | 3 payments
|
| Amarin Pharma | Vascepa | $165 | 13 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $133 | 2 payments
|
| Regeneron Healthcare Solutions | Praluent | $131 | 9 payments
|
| Abiomed | Impella | $125 | 1 payment
|
| Biosense Webster | Carto 3 System | $125 | 1 payment
|
| Cook Medical | Cook Medical Aaa | $124 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $123 | 6 payments
|
| Janssen Pharmaceuticals | Xarelto | $117 | 7 payments
|
| Actelion Pharmaceuticals US | Uptravi | $89 | 6 payments
|
| Asahi Intecc USA | Asahi Ptca Guide Wire | $88 | 1 payment
|
| Lundbeck | Northera | $86 | 4 payments
|
| Sanofi-Aventis U.S. | Praluent | $59 | 4 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $57 | 1 payment
|
| Terumo Medical | Metacross | $50 | 1 payment
|
| Gilead Sciences | Letairis | $45 | 2 payments
|
| Kowa Pharmaceuticals America | Livalo | $39 | 2 payments
|
| Akcea Therapeutics | Tegsedi | $28 | 1 payment
|
| Astellas Pharma US | Lexiscan | $24 | 1 payment
|
| Allergan | Bystolic | $13 | 1 payment
|
Professional record
- NPI
- 1821013889
- Licence
- CA A93963California A93963: Current · expires 2027-06-30
- Trained
- University of Southern California Keck School of Medicine, 2003
- Group
- Apex Cardiology of Silicon Valley A Medical Partnership · Physician Services at El Camino Hospital
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0011X (207RI0011X); Cardiology (207RC0000X)
- Mailing address
- 2400 Samaritan Dr, Suite 200, San Jose, CA, 95124
- NPI first listed
- 2006-07-12
- NPI last updated
- 2014-06-27
This is when the NPI record was last certified, not a medical board exam.